MIAMI, FL. JANUARY 3, 2019 – ArisGlobal, LLC, a leading provider of integrated cloud-based software solutions for life sciences, will present a session titled, “ArisGlobal Solution: Supporting Life Science Industry to Be Compliant with the New Regulation in China” at the upcoming 9th Asia Pharma R&D Leaders – Pharma & Healthcare to be held in Beijing from January 21-22, 2019.
Krishana Gopal Das, Head of Product Strategy, and Ye Zha, Executive Director, Greater China, ArisGlobal, will present the session, scheduled for January 21, 4:00 PM CST. Krishana and Ye will provide an overview of pharmacovigilance in China and the recent regulatory reforms made to achieve standards on par with leading health authorities.
“With the recent string of regulatory reforms and NMPA joining ICH, China is poised to catch up with the leading health authorities in bringing high-quality, low-cost, innovative solutions to its population and ensuring safe and effective use of medicinal products,” Krishana explained. “In addition to sharing an overview of pharmacovigilance in China, we will also share how drug manufacturers can comply with the new regulatory environment for drug safety in China using modern applications.”
ArisGlobal is a sponsor of this conference and will be exhibiting in booth #14. Attendees are welcome to visit and learn more about LifeSphere® MultiVigilance, the next-generation platform for individual case safety report (ICSR) intake powered by LifeSphere Nava – ArisGlobal’s cognitive computing engine.
ArisGlobal is a visionary technology company that’s transforming the way today’s most successful life sciences companies develop breakthroughs and bring new products to market. The ArisGlobal LifeSphere® cognitive technology platform integrates machine-learning capabilities to automate the core functions of the product lifecycle. Designed with deep expertise and a long-term perspective that spans more than 30 years, our cognitive platform delivers actionable insights, boosts efficiency, ensures compliance, and lowers total cost of ownership through multi-tenancy.